Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease

FASEB Journal

Volumn 28, Issue 6, 2014, Pages 2620-2631

  Stancu, Ilie Cosmin ^a   Ris, Laurence ^b   Vasconcelos, Bruno ^a   Marinangeli, Claudia ^a   Goeminne, Léonie ^a   Laporte, Vincent ^a   Haylani, Laetitia E ^a   Couturier, Julien ^a   Schakman, Olivier ^a   Gailly, Philippe ^a   Pierrot, Nathalie ^a   Kienlen Campard, Pascal ^a   Octave, Jean Noël ^a   Dewachter, Ilse ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

Author keywords

Amyloid plaques; GSK3; Hippocampal atrophy; Neurofibrillary tangles; Synaptic transmission

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; COGNITIVE DEFECT; CONTROLLED STUDY; GENE MUTATION; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MAZE TEST; MOUSE; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; TAUOPATHY; TRANSGENIC MOUSE;

AMYLOID PLAQUES; GSK3; HIPPOCAMPAL ATROPHY; NEUROFIBRILLARY TANGLES; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ATROPHY; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PRESENILIN-1; SYNAPTIC TRANSMISSION; TAU PROTEINS; TAUOPATHIES;

EID: 84901844853     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-246702     Document Type: Article

References (47)

1. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (Pubitemid 34790756)
2. Brunden, K. R., Trojanowski, J. Q., and Lee, V. M. (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Disc. 8, 783-793
3. Price, D. L., Tanzi, R. E., Borchelt, D. R., and Sisodia, S. S. (1998) Alzheimer's disease: genetic studies and transgenic models. Ann. Rev. Gen. 32, 461-493 (Pubitemid 29045321)
4. Ashe, K. H. (2001) Learning and memory in transgenic mice modeling Alzheimer's disease. Learn. Memory 8, 301-308
5. Duyckaerts, C., Potier, M. C., and Delatour, B. (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 5-38 (Pubitemid 50005258)
6. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., and Vassar, R. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (Pubitemid 44527407)
7. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V., Checler, F., Godaux, E., Cordell, B., and Van Leuven, F. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492 (Pubitemid 29111064)
8. Citron, M. (2004) Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 5, 677-685
9. Dewachter, I., and Van Leuven, F. (2002) Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol. 1, 409-416 (Pubitemid 37159151)
10. Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., Prinzen, C., Endres, K., Hiemke, C., Blessing, M., Flamez, P., Dequenne, A., Godaux, E., van Leuven, F., and Fahrenholz, F. (2004) A disintegrin- metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456-1464 (Pubitemid 39071701)
11. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (Pubitemid 29327547)
12. Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., Vassar, R., and Disterhoft, J. F. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33 (Pubitemid 38071826)
13. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405 (Pubitemid 32983430)
14. Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., Atzori, C., Migheli, A., Crowther, R. A., Ghetti, B., Spillantini, M. G., and Goedert, M. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340-9351 (Pubitemid 35356177)
15. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., and Lee, V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (Pubitemid 46161268)
16. Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P., and Van Leuven, F. (2005) Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 280, 3963-3973 (Pubitemid 40227485)
17. Gotz, J., Chen, F., Barmettler, R., and Nitsch, R. M. (2001) Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534 (Pubitemid 32050347)
18. Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buee, L., and Brion, J. P. (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 171, 976-992 (Pubitemid 47440995)
19. Schindowski, K., Bretteville, A., Leroy, K., Begard, S., Brion, J. P., Hamdane, M., and Buee, L. (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 169, 599-616 (Pubitemid 44156317)
20. Gotz, J., and Ittner, L. M. (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544 (Pubitemid 351873467)
21. Lewis, J., Dickson, D. W., Lin, W. L., Chisholm, L., Corral, A., Jones, G., Yen, S. H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., and McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (Pubitemid 32801551)
22. Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495 (Pubitemid 32807681)
23. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39, 409-421 (Pubitemid 36937044)
24. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., and LaFerla, F. M. (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 43, 321-332 (Pubitemid 39061125)
25. Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., and Van Leuven, F. (2008) Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172, 786-798 (Pubitemid 351354550)
26. Hurtado, D. E., Molina-Porcel, L., Iba, M., Aboagye, A. K., Paul, S. M., Trojanowski, J. Q., and Lee, V. M. (2010) Aβ accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am. J. Pathol. 177, 1977-1988
27. Saul, A., Sprenger, F., Bayer, T. A., and Wirths, O. (2013) Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol. Aging. 34, 2564-2573
28. Heraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J. N., and Brion, J. P. (2013) Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice. Neurobiol. Dis. 62C, 100-112
29. Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., and Jucker, M. (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol. 171, 2012-2020
30. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q., and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (Pubitemid 46717684)
31. Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G. Q., Palop, J. J., Noebels, J. L., and Mucke, L. (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711
32. Dewachter, I., Reverse, D., Caluwaerts, N., Ris, L., Kuiperi, C., Van den Haute, C., Spittaels, K., Umans, L., Serneels, L., Thiry, E., Moechars, D., Mercken, M., Godaux, E., and Van Leuven, F. (2002) Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J. Neurosci. 22, 3445-3453 (Pubitemid 37465750)
33. Gallyas, F. (1971) Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 19, 1-8
34. Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J. C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., Holscher, C., Arnold, S. E., Talbot, K., Klein, W. L., Munoz, D. P., Ferreira, S. T., and De Felice, F. G. (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J. Clin. Invest. 122, 1339-1353
35. Jack, C. R., Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., and Trojanowski, J. Q. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128
36. Jack, C. R., Jr., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216
37. St George-Hyslop, P. H., and Morris, J. C. (2008) Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372, 180-182 (Pubitemid 351997437)
38. Pigino, G., Pelsman, A., Mori, H., and Busciglio, J. (2001) Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J. Neurosci. 21, 834-842 (Pubitemid 32163124)
39. Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., and Wolozin, B. (1998) Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U.S.A. 95, 9637-9641 (Pubitemid 28506284)
40. Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., Macdonald, C., Aboagye, A. K., Trojanowski, J. Q., and Lee, V. M. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J. Neurosci. 32, 7392-7402
41. Selkoe, D. J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
42. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., and Ashe, K. H. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (Pubitemid 40994688)
43. Van der Jeugd, A., Hochgrafe, K., Ahmed, T., Decker, J. M., Sydow, A., Hofmann, A., Wu, D., Messing, L., Balschun, D., D'Hooge, R., and Mandelkow, E. M. (2012) Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 123, 787-805
44. Li, S., Shankar, G. M., and Selkoe, D. J. (2010) How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Front. Cell. Neurosci. 4, 5
45. Zahs, K. R., and Ashe, K. H. (2013) beta-Amyloid oligomers in aging and Alzheimer's disease. Front. Aging Neurosci. 5, 28
46. Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., Jucker, M., Goedert, M., and Tolnay, M. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913
47. De Calignon, A., Polydoro, M., Suarez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., Spires-Jones, T. L., and Hyman, B. T. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697